Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03998202 · ClinicalTrials.gov registry record
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
A clinical trial of Colorectal Cancer and Sarcopenia, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT03998202: Recruiting study of Colorectal Cancer and Sarcopenia, sponsored by Wake Forest University Health Sciences.
NCT03998202 is a study of Colorectal Cancer and Sarcopenia that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 300 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03998202, a study of Colorectal Cancer and Sarcopenia, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Primary Outcome
Chemotoxicity will be measured after initiation of chemotherapy using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).
Conditions Studied
Study Locations (20)
Illinois
- Illinois CancerCare-Bloomington - Bloomington
- Illinois CancerCare-Canton - Canton
- SIH Cancer Institute - Carterville
- John H Stroger Jr Hospital of Cook County - Chicago
- Carle at The Riverfront - Danville
- Cancer Care Specialists of Illinois - Decatur - Decatur
- Crossroads Cancer Center - Effingham
- Illinois CancerCare-Galesburg - Galesburg
- Carle Physician Group - Mattoon/Charleston - Mattoon
- SSM Health Good Samaritan - Mount Vernon
- Carle BroMenn Medical Center - Normal
- Carle Cancer Institute Normal - Normal
- Cancer Care Center of O'Fallon - O'Fallon
Delaware
- Beebe South Coastal Health Campus - Millville
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Beebe Health Campus - Rehoboth Beach
- Christiana Care Health System-Wilmington Hospital - Wilmington
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Georgia
- John B Amos Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2026-12-31 |
What NCT03998202 shows while recruiting
NCT03998202 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03998202 names 20 study sites across 4 states, led by Illinois, Delaware, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03998202 about?
NCT03998202 is a clinical study titled "Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer". This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
What is the current status of trial NCT03998202?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-09-23. Estimated completion is 2026-12-31.
What conditions does trial NCT03998202 study?
This clinical trial studies the following conditions: Colorectal Cancer, Sarcopenia.
Who is sponsoring clinical trial NCT03998202?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03998202 being conducted?
This trial has 20 study locations across Delaware, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03998202's enrollment target sits among peer trials
300 110th of 381 higher than 267 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI